Premium
Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor‐associated Antigen
Author(s) -
Snook A E,
Eisenlohr L C,
Rothstein J L,
Waldman S A
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100369
Subject(s) - antigen , medicine , colorectal cancer , context (archaeology) , immunotherapy , immune system , cancer , immunology , cancer immunotherapy , clinical pharmacology , disease , cancer research , biology , pharmacology , paleontology
Colorectal cancer is a leading cause of cancer‐related mortality worldwide. Surgery and chemoradiation exhibit incomplete efficacy and, ultimately, 50% of patients die of metastatic disease. In the context of that unmet clinical need, immunotherapeutic approaches have enjoyed limited success, partly because of a paucity of suitable antigen targets. However, exploitation of immune compartmentalization, employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors—cancer mucosa antigens (CMAs)—may represent a previously unrecognized class of immune targets supporting efficacious antitumor immunotherapy. Guanylyl cyclase C (GCC) is an intestine/colorectal cancer‐restricted protein ideally suited as the first CMA for clinical evaluation. Clinical Pharmacology & Therapeutics (2007) 82 , 734–739. doi: 10.1038/sj.clpt.6100369 ; published online 26 September 2007